Andrew C. Perkins

9.8k total citations · 2 hit papers
146 papers, 7.1k citations indexed

About

Andrew C. Perkins is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Andrew C. Perkins has authored 146 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Molecular Biology, 76 papers in Genetics and 62 papers in Hematology. Recurrent topics in Andrew C. Perkins's work include Kruppel-like factors research (50 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (48 papers) and Chronic Myeloid Leukemia Treatments (37 papers). Andrew C. Perkins is often cited by papers focused on Kruppel-like factors research (50 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (48 papers) and Chronic Myeloid Leukemia Treatments (37 papers). Andrew C. Perkins collaborates with scholars based in Australia, United States and United Kingdom. Andrew C. Perkins's co-authors include Michael R. Tallack, Sean M. Grimmond, Stuart H. Orkin, Brooke Gardiner, Stephen J. Bruce, Janelle R. Keys, Merlin Crossley, Graham Magor, Suzanne Cory and John S. Mattick and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Andrew C. Perkins

144 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Stem cell transcriptome profiling via massive-scale mRNA sequencing

2008 756 citations Andrew C. Perkins et al. profile →
Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation

2008 605 citations Marcel E. Dinger, Andrew C. Perkins et al. profile →

Peers

Andrew C. Perkins

GENET

HEMAT

GENET

Sjaak Philipsen Netherlands

Merlin Crossley Australia

Stephen A. Liebhaber United States

Tim M. Townes United States

Zuzana Tóthová United States

Stuart H. Orkin United States

Claus Nerlov United Kingdom

Benoı̂t Chabot Canada

Donald C. Foster United States

Dirk Heckl Germany

Sjaak Philipsen Netherlands

Andrew C. Perkins

6.1k ×1.2

1.4k ×1.0

GENET

813 ×0.6

948 ×0.8

HEMAT

1.2k ×1.4

GENET

Citations per year, relative to Andrew C. Perkins Andrew C. Perkins (= 1×) peers Sjaak Philipsen

Countries citing papers authored by Andrew C. Perkins

Since Specialization

Citations

This map shows the geographic impact of Andrew C. Perkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew C. Perkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew C. Perkins more than expected).

Fields of papers citing papers by Andrew C. Perkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew C. Perkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew C. Perkins. The network helps show where Andrew C. Perkins may publish in the future.

Co-authorship network of co-authors of Andrew C. Perkins

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew C. Perkins. A scholar is included among the top collaborators of Andrew C. Perkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew C. Perkins. Andrew C. Perkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tsang, Carmen, et al.. (2025). Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma. BMC Cancer. 25(1). 1219–1219. 1 indexed citations

Bose, Prithviraj, Hsin‐An Hou, Wojciech Homenda, et al.. (2024). Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis. Blood. 144(Supplement 1). 483–483. 3 indexed citations

Popov, Viola Maria, Sanjay Mohan, Zübeyde Nur Özkurt, et al.. (2024). Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis. Blood. 144(Supplement 1). 1000–1000. 4 indexed citations

Campbell, Erin J., Yvonne Bonomo, Lisa Collins, et al.. (2024). The dual orexin receptor antagonist suvorexant in alcohol use disorder and comorbid insomnia: A case report. SHILAP Revista de lepidopterología. 12(5). e8740–e8740. 4 indexed citations

Pemmaraju, Naveen, Tim C. P. Somervaille, Francesca Palandri, et al.. (2024). Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response. PubMed. 2(1). 100056–100056. 1 indexed citations

Harrison, Claire, Ruben A. Mesa, Moshe Talpaz, et al.. (2024). Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib. Clinical Lymphoma Myeloma & Leukemia. 25(3). 199–211. 2 indexed citations

Shore‐Lorenti, Catherine, Roger Zebaze, Peter G. Kerr, et al.. (2023). A Novel RUNX1 Genetic Variant Identified in a Young Male with Severe Osteoporosis. JBMR Plus. 7(9). e10791–e10791.

Pemmaraju, Naveen, Jacqueline S. Garcia, Andrew C. Perkins, et al.. (2023). New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy: Focus on clinical development of BCL‐X_L/BCL‐2 inhibition with navitoclax. Cancer. 129(22). 3535–3545. 12 indexed citations

Erber, Wendy N., et al.. (2023). Variability of bone marrow biopsy reporting affects accuracy of diagnosis of myeloproliferative neoplasms: data from the ALLG MPN01 registry. Pathology. 56(1). 75–80. 4 indexed citations

10.

Davis, Tracy, et al.. (2023). Vertical transmission of Renibacterium salmoninarum in cutthroat trout (Oncorhynchus clarkii). Journal of Fish Diseases. 46(4). 309–319. 2 indexed citations

11.

McFadyen, James D., et al.. (2023). Congenital fibrinogen disorders: Strengthening genotype–phenotype correlations through novel genetic diagnostic tools. British Journal of Haematology. 203(3). 355–368. 6 indexed citations

12.

Chan, Wing Fuk, Hannah D. Coughlan, Yunshun Chen, et al.. (2022). Activation of stably silenced genes by recruitment of a synthetic de-methylating module. Nature Communications. 13(1). 14 indexed citations

13.

Ghisi, Margherita, Mark McKenzie, H. L. Mitchell, et al.. (2021). Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy. Nature Communications. 12(1). 6546–6546. 8 indexed citations

14.

Millard, Susan, Anuj Sehgal, Katharine M. Irvine, et al.. (2021). Fragmentation of tissue-resident macrophages during isolation confounds analysis of single-cell preparations from mouse hematopoietic tissues. Cell Reports. 37(8). 110058–110058. 38 indexed citations

15.

Perkins, Andrew C., et al.. (2018). Investigation of the variable In(Lu) phenotype caused by KLF1 variants. Transfusion. 58(10). 2414–2420. 7 indexed citations

16.

Gloss, Brian, Bethany Signal, Seth W. Cheetham, et al.. (2017). High resolution temporal transcriptomics of mouse embryoid body development reveals complex expression dynamics of coding and noncoding loci. Scientific Reports. 7(1). 6731–6731. 11 indexed citations

17.

Papathanasiou, Peter, et al.. (2017). Impact of the c-MybE308G mutation on mouse myelopoiesis and dendritic cell development. PLoS ONE. 12(4). e0176345–e0176345. 5 indexed citations

18.

Gillinder, Kevin R., Graham Magor, Stephen Huang, et al.. (2017). Krüppel-like factors compete for promoters and enhancers to fine-tune transcription. Nucleic Acids Research. 45(11). 6572–6588. 42 indexed citations

19.

Perkins, Andrew C., et al.. (1997). Deficiency of the CACC-element binding protein, BKLF, leads to a progressive myeloproliferative disease and impaired expression of SHP-1.. Blood. 90(10). 2560–2560. 14 indexed citations

20.

Perkins, Andrew C., et al.. (1994). Erythroid Kruppel-Like Factor (Eklf) Knock-Out Mice Exhibit Selective Beta-Globin Deficiency and Die Prenatally From Anemia. Blood. 84(10). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact